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CASE REPORT
A case report of QT prolongation 
with glycopyrronium bromide in a patient 
with chronic tamoxifen use
Michael H. Chiu1, Nawaf S. Al‑Majed2, Ryan Stubbins3, Dylan Pollmann4 and Roopinder K. Sandhu2*
Abstract 
Background: Glycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy 
for moderate to severe chronic obstructive pulmonary disease (COPD). Efficacy and safety trial data have found rare 
cases of significant QT prolongation. To our knowledge, we describe the first case report of QT prolongation >600 ms 
with initiation of glycopyrronium bromide in a real world setting.
Case presentation: A 78‑year‑old female with moderate COPD recently started on glycopyrronium bromide, pre‑
sented to Emergency Department (ED) with syncope. Her past medical history was significant for a left total mastec‑
tomy and she had been on Tamoxifen for 9 months. One day prior to her presentation, she had visited a naturopathic 
clinic for a vitamin infusion resulting in emesis. The following day she continued to feel dizzy and had a witnessed 
syncopal episode without any reported cardiac or neurological symptoms preceding the event or after regaining con‑
sciousness. In the emergency department, she reported dizziness and was found to be hypotensive. Her symptoms 
completely resolved with intravenous fluids. Lab work was normal however her electrocardiogram (ECG) demon‑
strated a QTc interval of 603 and 631 ms (Friderica and Bazett’s respectively) with a normal QT interval on her baseline 
ECG prior to initiating Tamoxifen. She was admitted to the Cardiology service for further work‑up of QT prolongation. 
Her syncope was felt to be due to orthostatic hypotension and the QT prolongation secondary to medications, which 
were both discontinued during her admission. After 2 days, her QT interval normalized consistent with the half‑life of 
Glycopyrronium bromide (13–57 h) compared to Tamoxifen (8–14 days).
Conclusion: Glycopyrronium bromide is guideline recommended as first line therapy for prevention of exacerbation 
in moderate to severe COPD however safety data had been limited to select populations. This case report highlights 
the need for future studies to identify high‑risk populations at potential risk of life‑threatening arrhythmias who may 
benefit from periodic ECG surveillance.
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Background
Chronic obstructive pulmonary disease (COPD) is a 
common condition, comprising of a spectrum of emphy-
sema, bronchitis and bronchiolitis that involves paren-
chymal destruction and infiltration [1]. Pharmacologic 
maintenance therapy for COPD involves bronchodilation 
via β-2 adrenergic agonist, corticosteroids, anticholiner-
gics and long acting muscarinic antagonists (LAMA) [2]. 
Glycopyrronium bromide (GB) is a recently approved 
synthetic competitive muscarinic antagonist that acts at 
the bronchial smooth muscle and inhibits acetylcholine-
mediated bronchoconstriction. GB is recommended as 
first line therapy for preventing exacerbations in moder-
ate to severe COPD [3].
Efficacy and safety trial data in selected populations 
have found variable results regarding QT prolonging 
effects with GB therapy and rare cases of QT prolonga-
tion  >500  ms [4–9]. A small, randomized controlled 
study found no repolarization abnormalities with a single 
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supra-therapeutic dosing of GB in young, healthy adults 
[10]. After extensive investigation and consideration of 
other possible offending medication, we report here the 
first case of severe and transient QT prolongation con-
sistent with pharmacokinetics of GB in the real-world 
setting.
Case presentation
A 78-year-old female with a past medical history signifi-
cant for breast cancer and moderate COPD presented 
to Emergency Department with syncope. Nine months 
prior to admission, she underwent left total mastectomy 
for invasive ductal carcinoma and was started on Tamox-
ifen 20 mg daily. Home medications included GB 50 mcg 
once daily, Salbutamol, calcium and a multi-vitamin. 
GB was started 3  months prior to her presentation for 
syncope.
The day prior to admission, she received an IV vita-
min infusion consisting of a mixture of thiamine, folic 
acid, multivitamin and magnesium sulfate at a naturo-
path clinic. Shortly after completion of the IV infusion, 
she developed emesis and took 2 tablets of dimenhydri-
nate. The following day, she reported dizziness as she 
walked across the kitchen and passed out after sitting in 
a chair. The patient reported no palpitations, chest dis-
comfort, nausea, warm sensation or diaphoresis prior 
to the syncope event. She was not witnessed to have any 
seizure like activity and when she regained conscious-
ness, reported immediate awareness of surroundings 
with no neurological deficits, no tongue biting, bowel 
or urinary incontinence. There was no previous his-
tory of syncope and no family history of sudden car-
diac death. Her initial blood pressure in the ambulance 
was 70/50  mm  Hg. Hemodynamics normalized after 
administration of intravenous fluid and her symptoms 
resolved. Oxygen saturation was above 97 % and telem-
etry revealed normal sinus rhythm with a heart rate of 
77. Precordial examination was unremarkable with regu-
lar normal heart sounds and no murmurs. In the Emer-
gency Department, blood tests including complete blood 
count (CBC), serum electrolytes (potassium, calcium, 
magnesium), glucose, creatinine and thyroid stimulat-
ing hormone were normal. Electrocardiogram (ECG) 
showed a corrected QT interval using Fridericia (QTcF) 
and Bazett’s formula (QTcB) of 603 and 631 ms respec-
tively (Fig.  1) and she was admitted to the cardiology 
service for further investigation of the etiology for her 
QT prolongation.
Prior to starting Tamoxifen her QTcF and QTcB were 
439 and 440  ms respectively (Fig.  2), however no ECG 
was obtained after initiation of Tamoxifen and prior to 
starting GB. Her last dose of Tamoxifen and GB were the 
day of admission with both medications discontinued at 
presentation.
An echocardiogram revealed that her left ventricular 
ejection fraction was >60 % with no valvular or regional 
wall motion abnormalities. Serial electrocardiograms 
demonstrated corrected QTcF and QTcB respectively of 
Fig. 1 Electrocardiogram at hospital presentation demonstrating prolonged corrected QT intervals of 603 ms using Fridericia’s equation and 
631 ms using Bazett’s formula
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603 and 631 ms day 0, 496 and 514 ms day 1, and 446 and 
455 ms on day 2 and 442 and 460 ms on day 3 (Fig. 3). 
There were no arrhythmias seen on telemetry. Syncope 
was felt to be secondary to orthostatic changes and she 
was discharged on day 3 after admission.
Discussion
The QT interval represents the time interval between the 
onset of the QRS complex and the end of the T wave includ-
ing ventricular depolarization and repolarization. There are 
many factors that can induce QT prolongation including left 
Fig. 2 Electrocardiogram prior to starting Tamoxifen with corrected QT intervals of 439 ms using Fridericia’s equation and 440 ms using Bazett’s 
formula
Fig. 3 Electrocardiogram 72 h after stopping glycopyrronium with corrected QT intervals of 442 ms using Fridericia’s equation and 460 ms using 
Bazett’s formula
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ventricular hypertrophy, heart failure, myocardial ischemia, 
hypertension, diabetes, thyroid dysfunction, bradycardia 
and electrolyte abnormalities including hypokalemia and 
hypomagnesaemia. Congenital long QT syndrome (LQTS) 
is due to direct mutations in specific genes such as the car-
diac delayed rectifier potassium channel (KCNQ1 and 
KCNH2) or the cardiac sodium channel (SCN5A). In con-
genital LQTS, exercise, emotional or physical stress is pre-
sumed to be an underlying trigger for long QT events. Aside 
from congenital LQTS, there is a 30 % heritability of the QT 
interval in the general population [11].
Medications represent one of the largest causes of pro-
longed QT [12]. The primary mechanism of drug induced 
QT prolongation is blockade of the rapid component of 
the delayed rectifier potassium channel leading to pro-
longed action potential duration [13]. Drugs that inhibit 
the human ether-à-go-go-related gene (hERG) K+ chan-
nel have the highest risk of QT prolongation. HERG 
inhibition increasing susceptibility to early after depolari-
zation that can result in torsades de pointes (TdP) and a 
risk of sudden cardiac death [11, 12, 14].
In our case, the possible offending drugs responsi-
ble for QT prolongation were GB and Tamoxifen. The 
pharmacokinetics of the two drugs differs considerably; 
the half-life of GB is 13–57 h while that of Tamoxifen is 
4–9 days with a single dose. Clinical studies of QT pro-
longation associated with Tamoxifen reported normali-
zation of the QT interval within 8–14  days after drug 
cessation [15, 16]. There are no known drug interactions 
between the anticholinergic properties of GB and estro-
gen receptor properties of Tamoxifen and both have dif-
ferent excretion pathways [17]. The mechanism of action 
for GB is via Muscarinic M1 and M3 receptor blockade, 
which prevents parasympathetic mediated bronchoc-
onstriction [18]. GB has less selectivity toward the M2 
receptor present in the heart, pacemaker cells and con-
duction system [18].
In experimental studies, the effects on the hERG K+ 
channel blockade channels have previously been exam-
ined during product safety development. In-vitro patch 
clamp experiments reported a progressive dose depend-
ent inhibition of hERG current [19]. Inhibition of the 
hERG current was 0.6  % for the vehicle and 13.2, 18.3 
and 30.6  % for 3.2, 31.8 and 95.5  μg/mL of GB respec-
tively. Novartis product normogram mentions an IC50 
value of  >300μM, which is greater than 500,000 times 
of the maximal recommended concentration Cmax [19, 
20]. Electrophysiological rabbit studies reported no 
proarrhythmic activity at supertherapeutic dosing. Fur-
thermore, telelmetry studies on beagle dogs with super-
therapeutic IV GB (12  >  Cmax in humans) reporting a 
transient QTc shortening of up to 30 s observed for up to 
2 h [20].
In clinical studies, the safety and efficacy of GB have 
been studied in six randomized controlled studies (GLy-
copyrronium bromide in COPD airWays—GLOW) 
[4–9]. The safety profile testing for GB in the GLOW 
trials excluded patients with a QTc greater than 450 ms 
in males and 470  ms in females. Other exclusion crite-
ria included moderate or severe renal dysfunction, prior 
lung cancer, active infection, urinary retention or history 
of alpha 1 anti-trypsin. A history of breast cancer was not 
specifically reported as an exclusion criterion. Three of 
these trials reported slightly variable results ranging from 
no significant incidence to low incidence of QT prolon-
gation in GB compared to placebo or active comparator, 
and rare reports of QT prolongation  >500  ms (Table  1) 
[4–9]. In the GLOW trials no significant QT prolonga-
tion was noted between GB versus placebo. The variable 
QT results in the GLOW trials prompted a randomized, 
partially blind, placebo and positive (moxifloxacin) con-
trol, 3 way cross-over study among 73 healthy adults 
[10]. Compared to placebo, no significant QT prolong-
ing effect was observed after inhalation of a single supra-
therapeutic (400 μg) dose of GB.
Conclusion
Glycopyrronium bromide is guideline recommended as 
first line therapy for prevention of exacerbation in mod-
erate to severe COPD however safety data particularly 
in regards to QT prolongation has been limited to select 
populations. In our case, we demonstrate severe QT 
prolongation associated with Glycopyrronium bromide, 
emphasizing the need for further studies in a real-world 
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Table 1 Summary Table of the glycopyrronium QTCF effects in the GLOW 1–6 trials (the GB in COPD airWays studies)[4–9]





 Efficacy, safety and toler‑
ability of GB in moderate/
severe COPD
Study type
 Randomized controlled trial 
double blind
Size
 n = 822
Inclusion criteria
 GOLD criteria—moderate to severe ≥40 years of 
age
 Smoking history of ≥10 pack‑years
 Exclusion criteriaPost‑bronchodilator FEV1 of <80 
and ≥30 % of predicted FEV1/FVC ratio of <0.70
 Lower respiratory tract infection (RTI) within 
6 weeks; concomitant pulmonary disease history 
of asthma or lung cancer
 Long QT syndrome: QTc >450 ms (males) or >470 
(females)
 Symptomatic prostatic hyperplasia
 Bladder‑neck obstruction
 Moderate/severe renal impairment
 Urinary retention
 Narrow—angle glaucoma
 History of alpha‑1 antitrypsin
Intervention
 GB n = 552, completed 26 week 
trial n = 450
Comparator
 Placebo n = 270, completed 
26 week trial n = 212
QTcF >500 ms
 GB: n = 0 (0 %)
Placebo: n = 0 (0 %)
 Increase of 30–60 ms
 GB: n = 59 (10.7 %)
Placebo n = 21 (7.9 %)
Increase of >60 ms
 GB: n = 6 (1.1 %)
 Placebo: n = 1 (0.4 %)
GLOW‑2
Aim
 Efficacy, safety and toler‑
ability of GB in moderate/
severe COPD vs placebo vs 
tiotropium
Study type
 Randomized controlled trial 
(double blind)
Size
 n = 1066
Inclusion criteria
 Males and females ≥40 years of age
 Smoking history of ≥10 pack‑years
 GOLD moderate‑to‑severe COPD
 Post‑bronchodilator FEV1 ≥30 and <80 % of the 
predicted
 Post‑broncho‑dilator FEV1/FVC <0.70
Exclusion criteria
 Lower RTI 6 weeks prior
 Concomitant pulmonary disease
Intervention
 GB n = 529, completed 52 week 
trial n = 411
 Comparator
Placebo n = 269, completed 
52 week trial n = 193
 Tiotropium n = 268 completed 
52 week trial n = 206
QTcF >500 ms
 GB: n = 2 (0.4 %)
 Placebo: n = 2 (0.7 %)
 Tiotropium: n = 0 (0 %)
Increase of 30–60 ms:
 GB: n = 83 (15.8 %)
 Placebo: n = 39 (14.6 %)
 Tiotropium: n = 43 (16.2 %)
Increase of >60 ms
 GB: n = 1 (0.2 %)
 Placebo: n = 1 (0.4 %)
 Tiotropium: n = 0 (0 %)  Pulmonary tuberculosis
  Bronchiectasis
  History of asthma
  Malignancy of any system
 Long QT syndrome or QTc >450 ms (males) or >470 
(females)
 Symptomatic prostatic hyperplasia
 Bladder‑neck obstruction
 Moderate/severe renal impairment
 Urinary retention
 Narrow‑angle glaucoma
 History of a1‑antitrypsin deficiency
 Active in pulmonary rehabilitation
 Contraindications for tiotropium or ipratropium or 




Exercise tolerance with once 
daily GB
Study type
 Randomized Controlled Trial 
(Double blind)
Size
 n = 108
Inclusion criteria
 GOLD moderate to severe COPD
 Aged ≥ 40 years
 Smoking history ≥10 pack‑years
 Post‑bronchodilator FEV1 <80 %
 ≥40 % of predicted normal
 Post‑bronchodilator FEV1/FVC of <70 %.
Exclusion criteria
 Lower RTI prior 6 weeks
 Oxygen for chronic hypoxemia
 Concomitant pulmonary disease
Intervention
 GB n = 55
Comparator
 Placebo n = 53
QTcF—not measured
  Pulmonary tuberculosis
  Bronchiectasis
  History of asthma
  Malignancy of any system
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Table 1 continued
Aim of study; study size (N) Patient population Study intervention
Study comparator
QT prolongation
 Long QT syndrome QTc >450 ms for males 
or >470 ms for females,
 Symptomatic prostatic hyperplasia
 Bladder‑neck obstruction
 Moderate/severe renal impairment
 Urinary retention
 Narrow‑angle glaucoma
 Alpha‑1 anti‑ trypsin deficiency
 Adverse reactions to inhaled anticholinergic agents, 
long‑ and short‑acting alpha‑agonists or
 Sympathomimetic amines
 Active pulmonary rehabilitation
GLOW‑4
Aim
Efficacy, safety and toler‑
ability of GB in moderate/
severe COPD vs tiotropium 
in the Japanese Population
Study type
 Randomized controlled trial 
(Double blind)
Size
 n = 163
Inclusion criteria
 GOLD moderate‑to‑severe COPD
 Males and females ≥40 years of age
 Smoking history of ≥10 pack‑years GOLD moderate‑
to‑severe COPD
 Post‑bronchodilator FEV1 ≥30 and
 <80 % of the predicted Post‑broncho‑dilator FEV1/
FVC <0.70
Exclusion criteria
 Lower RTI prior 6 weeks
 Oxygen for chronic hypoxemia
 Concomitant pulmonary disease
Intervention
 GB n = 123
Comparator
 Placebo n = 40
QTcF—not measured
  Pulmonary tuberculosis
  Bronchiectasis
  History of asthma
  Malignancy of any system
 Long QT syndrome QTc >450 ms for males 
or >470 ms for females,
 Symptomatic prostatic hyperplasia
 Bladder‑neck obstruction
 Moderate/severe renal impairment
 Urinary retention
 Narrow‑angle glaucoma
 Alpha‑1 anti‑ trypsin deficiency
 Adverse reactions to inhaled anticholinergic 
agents, long‑ and short‑acting alpha‑agonists or 
sympathomimetic amines
 Active pulmonary rehabilitation
GLOW‑5
Aim
Efficacy, safety and toler‑
ability of GB in moderate/
severe COPD vs once daily 
tiotropium
Study type
 Randomized controlled trial 
(double blind)
Size
 n = 657
Inclusion criteria
GOLD moderate‑to‑severe COPD
 Males and females ≥40 yrs of age
 Smoking history of ≥10 pack‑yrs
 GOLD moderate‑to‑severe COPD
 Post‑bronchodilator FEV1 ≥30 % and <80 % of the 
predicted Post‑broncho‑dilator FEV1/FVC <0.70
Exclusion criteria
 Lower RTI prior 6 weeks
 Oxygen for chronic hypoxemia
 Concomitant pulmonary disease
Intervention
 GB n = 327, completed 12 week 
trial n = 314
Comparator
 Tiotropium n = 320, completed 
12 week trial n = 316
QTcF >480 ms
 GB: n = 2 (0.64) %
 Tiotropium: n = 0 (0 %)
QTcF increase 30–60 ms:
 GB: n = 11 (3.4 %)
 Tiotropium: n = 10 (3 %)
  Pulmonary tuberculosis
  Bronchiectasis
  History of asthma
  Malignancy of any system
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setting to identify high-risk patients that may benefit 
from ECG surveillance.
Abbreviations
COPD: chronic obstructive pulmonary disease; ED: Emergency Department; 
ECG: electrocardiogram; LAMA: long acting muscarinic antagonists; GB: glyco‑
pyrronium bromide; CBC: complete blood count; QTcF: corrected QT interval 
using Fridericia; QTcB: corrected QT interval using Bazett’s formula; LQTS: long 
QT syndrome; TdP: torsades de pointes; GLOW: gLycopyrronium bromide in 
COPD airways.
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Table 1 continued
Aim of study; study size (N) Patient population Study intervention
Study comparator
QT prolongation
 Long QT syndrome QTc > 450 ms for males 
or > 470 ms for females,
 Symptomatic prostatic hyperplasia
 Bladder‑neck obstruction
 Moderate/severe renal impairment
 Urinary retention
 Narrow‑angle glaucoma
 Alpha‑1 anti‑ trypsin deficiency
 Adverse reactions to inhaled anticholinergic 
agents, long‑ and short‑acting alpha‑agonists or 
sympathomimetic amines
 Active pulmonary rehabilitation
GLOW‑6
Aim
Efficacy, safety and tolerabil‑
ity of GB and indacaterol vs 
indacaterol alone in moder‑
ate/severe COPD
Study type
 Randomized controlled trial 
(double blind)
Size
 n = 449
Inclusion criteria
 GOLD moderate‑to‑severe COPD
 Males and females ≥ 40 yrs of age
 Smoking history of ≥ 10 pack‑yrs
 GOLD moderate‑to‑severe COPD
 Post‑bronchodilator FEV1 ≥ 30 % and < 80 % of the 
predicted Post‑broncho‑dilator FEV1/FVC < 0.70
Exclusion criteria
 Lower RTI prior 6 weeks
 Oxygen for chronic hypoxemia
 Concomitant pulmonary disease
Intervention
 GB + Indacaterol n = 226
Completed 12 week trial n = 212
Comparator
 Indacaterol n = 223 completed 
12 week trial n = 210
QTcF >500 ms:
 GB +Ind: n = 0 (0 %)
 Ind: n = 0 (0 %)
QTcF increase 30–60 ms:
 GB + Ind: n = 14 (6.5 %)
 Ind: n = 9 (4.2 %)
  Pulmonary tuberculosis
  Bronchiectasis
  History of asthma
  Malignancy of any system
 Long QT syndrome QTc > 450 ms for males 
or > 470 ms for females,
 Symptomatic prostatic hyperplasia
 Bladder‑neck obstruction
 Moderate/severe renal impairment
 Urinary retention
 Narrow‑angle glaucoma
 Alpha‑1 anti‑ trypsin deficiency
 Adverse reactions to inhaled anticholinergic 
agents, long‑ and short‑acting alpha‑agonists or 
sympathomimetic amines
 Active pulmonary rehabilitation
 Atrial fibrillation
 NYHA III or IV symptoms
FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, RTI respiratory tract infection
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